Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response 1,2 . Anti-PD-1 antibodies have shown remarkable promise in treating tumours, including metastatic melanoma 2-4 . However, the patient response rate is low 4,5 . A better understanding of PD-L1-mediated immune evasion is needed to predict patient response and improve treatment efficacy. Here we report that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface. Stimulation with interferon-γ (IFN-γ) increases the amount of PD-L1 on these vesicles, which suppresses the function of CD8 T cells and facilitates tumour growth. In patients with metastatic melanoma, the level of circulating exosomal PD-L1 positively correlates with that of IFN-γ, and varies during the course of anti-PD-1 therapy. The magnitudes of the increase in circulating exosomal PD-L1 during early stages of treatment, as an indicator of the adaptive response of the tumour cells to T cell reinvigoration, stratifies clinical responders from non-responders. Our study unveils a mechanism by which tumour cells systemically suppress the immune system, and provides a rationale for the application of exosomal PD-L1 as a predictor for anti-PD-1 therapy.
extracellular domain to inactivate T cells 2, 3, 14 . Using immuno-electron microscopy and enzyme-linked immunosorbent assay (ELISA) ( Fig. 1e-g) , we found that exosomal PD-L1 has the same membrane topology as cell surface PD-L1, with its extracellular domain exposed on the surface of the exosomes. Exosomal PD-L1 binds PD-1 in a concentration-dependent manner, and this interaction can be disrupted by PD-L1-blocking antibodies (Fig. 1h) . Furthermore, the level of exosomal PD-L1 secreted by melanoma cells increased markedly upon IFN-γ treatment ( Fig. 1f , g, i), and correspondingly, these exosomes displayed increased binding to PD-1 (Fig. 1h ).
Exosomes are generated and released through a defined intracellular trafficking route 7, 9, 10 . Genetic knockdown of the ESCRT subunit Hrs, which mediates the recognition and sorting of exosomal cargos 15 , using short hairpin (sh)RNA led to a decrease in the level of PD-L1 in the exosomes and an increase of PD-L1 in the cell (Extended Data Fig. 1g, h ). In addition, PD-L1 co-immunoprecipitated with Hrs from cell lysates (Extended Data Fig. 1i ). PD-L1 co-localized with Hrs and CD63, an exosome marker, in melanoma cells (Extended Data Fig. 1j, k) . Knockdown of Rab27A, which mediates exosome release 16 , also blocked PD-L1 secretion via the exosomes (Extended Data Fig. 1l ).
To investigate the secretion of exosomal PD-L1 by melanoma cells in vivo, we established human melanoma xenografts in nude mice. Blood from these mice was collected for exosome purification and subsequent detection of human PD-L1 proteins by ELISA ( Fig. 2a ). Antibodies against human PD-L1 specifically identified human PD-L1 on the circulating exosomes from mice bearing human melanoma xenografts but not the control mice ( Fig. 2b , Extended Data Fig. 2a, b) . Moreover, the level of circulating exosomal PD-L1 positively correlated with tumour size (Fig. 2c ).
PD-L1 has been found in blood samples derived from melanoma patients 17 . Recent studies suggest the presence of PD-L1 in extracellular vesicles isolated from blood samples of patients with cancer, and the level of PD-L1 correlates with pathological features of these patients [18] [19] [20] . We purified extracellular vesicles from the plasma of melanoma patients (Extended Data Fig. 2c-g) . The level of PD-L1 on the circulating exosomes was significantly higher in patients with metastatic melanoma than in healthy donors ( Fig. 2d , Extended Data Figs. 2f, 3a, 3b), whereas there was no or only marginal difference in the number of circulating exosomes or the total protein level on these exosomes (Extended Data Fig. 3c, d ). There was less difference in PD-L1 levels in circulating microvesicles compared to the circulating exosomes (Extended Data Fig. 3e ). The data analysis and receiver operating characteristic (ROC) curve show that, among all the parameters tested, 10) . d-f, ELISA of circulating exosomal PD-L1 (d), total PD-L1 (e) or extracellular vesicle (EV)-excluded PD-L1 (f) in healthy donors (HD, n = 11) and melanoma patients (MP, n = 44). The exosomes were purified using the exosome isolation kit. g, ROC curve analysis for the indicated parameters in patients with metastatic melanoma compared to healthy donors. Data are mean ± s.d. P values are from a two-sided unpaired t-test (b, d-f). Letter reSeArCH the level of circulating exosomal PD-L1 best distinguished melanoma patients from healthy donors ( Fig. 2d -g, Extended Data Fig. 3e , f).
The current model for PD-L1-mediated immunosuppression is based on the interaction between PD-L1 on the tumour cell surface and PD-1 on CD8 T cells. Here we tested whether exosomal PD-L1 inhibits CD8 T cells. First, we used confocal microscopy to show a physical interaction between tumour exosomes and CD8 T cells purified from human peripheral blood (Extended Data Fig. 4a, b ). Flow cytometry analyses further indicated that the level of interaction was higher for activated CD8 T cells than for non-activated counterparts (Extended Data Fig. 4c ). Moreover, exosomes derived from melanoma cells treated with IFN-γ exhibited a higher level of binding to CD8 T cells (Extended Data Fig. 4d ). Next, we tested the effect of exosomal PD-L1 on CD8 T cells, taking advantage of MEL624 cells, which do not express endogenous PD-L1 (Extended Data Fig. 5a-d ) and other immunosuppressive proteins such as FasL and TRAIL 1 . Exosomes derived from MEL624 cells expressing exogenous PD-L1 inhibited the proliferation, cytokine production and cytotoxicity of CD8 T cells, as demonstrated by the decreased proportion of cells containing diluted carboxyfluorescein succinimidyl ester (CFSE, a cell division-tracking dye), reduced expression of Ki-67 and granzyme B (GzmB), and the inhibited production of IFN-γ, IL-2, and TNF ( Fig. 3a , Extended Data Fig. 5e , f). Pre-treatment of the exosomes with anti-PD-L1 antibodies nearly abolished these effects. Similar effects were observed using exosomes secreted from WM9 cells, which express endogenous PD-L1 (Extended Data Fig. 5e -h). Exosomes derived from mouse melanoma B16-F10 cells also inhibited the proliferation and cytotoxicity of mouse splenic CD8 T cells (Extended Data Fig. 6a-d ). Pre-treating OT-I T cells (which specifically recognize OVA peptide) (Extended Data Fig. 6e ) with B16-F10 cell-derived exosomes inhibited their ability to kill their target cells (Extended Data Fig. 6f ). Extracellular vesicles from human lung and breast cancer cells also contain immunosuppressive PD-L1, mostly of which is in exosomes, and PD-L1 expression is also upregulated by IFN-γ in some of these cell lines (Extended Data Fig. 7a -e).
To examine the effects of exosomal PD-L1 in vivo, we established a syngeneic mouse melanoma model in C57BL/6 mice using B16-F10 cells in which PD-L1 expression had been knocked down (PD-L1(KD) B16-F10) (Extended Data Fig. 8a ). Injection of exosomes derived from parental B16-F10 cells promoted the growth of tumours derived from PD-L1(KD) B16-F10 cells, whereas pre-treatment of the exosomes with anti-PD-L1 antibodies, but not with IgG isotype or CD63-blocking antibodies, inhibited the effect (Fig. 3b , Extended Data Fig. 8b , c). The number of tumour-infiltrating CD8 T lymphocytes (TILs) decreased significantly after the injection of exosomes ( Fig. 3c , Extended Data Fig. 8d, e ). B16-F10 exosomes also decreased the proportion of proliferating PD-1 + CD8 T cells in both spleen and lymph nodes ( Fig. 3c , Extended Data Fig. 8d ), suggesting that exosomal PD-L1 suppresses anti-tumour immunity systemically.
We then examined the level of PD-L1 on circulating extracellular vesicles in melanoma patients during anti-PD-1 therapy. The pre-treatment level of circulating exosomal PD-L1 was significantly higher in patients who failed to respond to the anti-PD-1 treatment with pembrolizumab ( Fig. 4a) . The difference was, however, not significant for total circulating PD-L1, and undetectable for PD-L1 on circulating microvesicles, or extracellular vesicle-excluded PD-L1 ( Fig. 4b-d ). A higher level of circulating exosomal PD-L1 before the treatment was associated with poorer clinical outcomes ( Fig. 4e ). IFN-γ upregulates exosomal PD-L1 and the pre-treatment levels of IFN-γ were significantly higher in patients who did not respond to pembrolizumab 21 . The level of circulating exosomal PD-L1 positively correlated with the level of circulating IFN-γ and overall tumour burden ( Fig. 4f, g) , which were shown to be indicative of poor prognosis 21 . 
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Next, we examined the level of circulating exosomal PD-L1 in patients undergoing pembrolizumab therapy. In clinical responders, there were increased levels of PD-L1 on circulating exosomes, mostly within 6 weeks of therapy ( Fig. 4h, i) . The level of PD-L1 on microvesicles also increased in the same cohort of patients, but to a lesser extent in comparison to exosomes (Extended Data Fig. 9a ). Proliferation and reinvigoration of CD8 T cells peaked at week 3 of treatment and preceded the peaking of exosomal PD-L1 at week 6 (Extended Data Fig. 9b ). Moreover, in pembrolizumab-responsive patients, both the absolute value and maximal fold change of Ki-67 in PD-1 + CD8 T cells after 3-6 weeks of treatment positively correlated with those of circulating exosomal PD-L1 (Extended Data Fig. 9c, d) . The responders displayed a larger increase in the level of circulating exosomal PD-L1 as early as 3-6 weeks following the initial treatment ( Fig. 4j ). ROC analysis determined that a fold change of 2.43 in exosomal PD-L1 at week 3-6 stratified patients by clinical response to pembrolizumab (Fig. 4k ); a fold change in circulating exosomal PD-L1 greater than 2.43 at week 3-6 was associated with a better response to anti-PD-1 therapy by objective response rate (ORR), progression-free and overall survival ( Fig. 4l , Extended Data Fig. 9e ). The fold increase of total circulating PD-L1, microvesicle PD-L1, and extracellular vesicle-excluded PD-L1 was inferior to that of exosomal PD-L1 for distinguishing responders from non-responders ( Fig. 4k , m-o, Extended Data Fig. 9f-h) .
Our studies suggest that melanoma cells release PD-L1-positive extracellular vesicles into the tumour microenvironment and circulation to counter the anti-tumour immunity systemically. Since exosomal PD-L1-mediated T cell inhibition can be blocked by antibodies against either PD-L1 or PD-1, our results raise the possibility that disrupting the interaction between exosomal PD-L1 and PD-1 on T cells is a previously unrecognized mechanism in PD-L1/PD-1 blockade-based therapies. The level of PD-L1 on extracellular vesicles is upregulated by IFN-γ, and PD-L1 on extracellular vesicles primarily targets PD-1 + CD8 T cells, which represent the antigen-experienced T cells that secrete IFN-γ. Exosomal PD-L1 may therefore reflect the dynamic interplay between tumour and immune cells. Besides PD-L1, other extracellular vesicle proteins such as FasL may also contribute to immunosuppressive effects 19, [22] [23] [24] . However, PD-L1 enables exosomes to target predominantly PD-1 + CD8 T cells, allowing tumour cells to counteract the immune pressure at the effector stage. In addition to the interaction between exosomal-PD-L1 and PD-1, the involvement of other molecules including B7 and CD28 25, 26 in this process also warrant investigation.
Our study suggests that circulating exosomal PD-L1 prior to and during pembrolizumab treatment may reflect distinct states of anti-tumour immunity. The pre-treatment PD-L1 level may correlate with a role of exosomal PD-L1 in immune dysfunction. High levels of exosomal PD-L1 may reflect the 'exhaustion' of T cells to a stage at which they can no longer be reinvigorated by anti-PD-1 treatment. In on-treatment patients, however, an increase in the level of exosomal PD-L1, following and correlating positively with T cell reinvigoration, Letter reSeArCH would reflect the presence of a successful anti-tumour immunity elicited by the anti-PD-1 therapy. Although the increase in exosomal PD-L1 in response to IFN-γ could enable tumour cells to adaptively inactivate CD8 T cells, this is futile because the interaction between PD-L1 and PD-1 is blocked by pembrolizumab. We observed no marked increase in exosomal PD-L1 in non-responders. This could be a result of failure to elicit an adequate T cell response, or a resistance mechanism to IFN-γ from tumours. Tumour cells in non-responders may have adaptively downregulated their response to IFN-γ to avoid the detrimental increase in antigen presentation and to escape the anti-proliferative effects induced by IFN-γ 5, 27 .
Our study offers a rationale for developing circulating exosomal PD-L1 as a predictor for the clinical outcomes of anti-PD-1 therapy, and sheds light on possible causes for the failure of anti-PD-1 therapies experienced by many patients (Extended Data Fig. 10 ). Tumour PD-L1 has been used as a predictive biomarker for clinical responses to anti-PD-1 therapy [28] [29] [30] . Considering the heterogeneity and dynamic changes of PD-L1 expression in tumours, and the invasive nature of tumour biopsy, developing exosomal PD-L1 as a blood-based biomarker could be an attractive option.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10. Flow cytometry of patients' PBMCs. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll gradient and stored using standard protocols. Cryopreserved PBMC samples from pretreatment, cycles 1-4 (weeks 3-12) were thawed and analysed by flow cytometry as previously described 21 . In brief, live or dead cell discrimination was performed using Live/Dead Fixable Aqua Dead Cell Stain Kit (Life Technologies). Cell surface staining was performed for 30 min at 4 °C. Intracellular staining was performed for 60 min on ice after using a fixation/ permeabilization kit (eBioscience).
Purification of extracellular vesicles. For exosome purification from cell culture supernatants, cells were cultured in media supplemented with 10% exosomedepleted FBS. Bovine exosomes were depleted by overnight centrifugation at 100,000g. Supernatants were collected from 48-72 h cell cultures and extracellular vesicles were purified by a standard differential centrifugation protocol [9] [10] [11] [12] . In brief, culture supernatants were centrifuged at 2,000g for 20 min to remove cell debris and dead cells (Beckman Coulter, Allegra X-14R). Microvesicles were pelleted after centrifugation at 16,500g for 45 min (Beckman Coulter, J2-HS) and resuspended in PBS. Supernatants were then centrifuged at 100,000g for 2 h at 4 °C (Beckman Coulter, Optima XPN-100). The pelleted exosomes were suspended in PBS and collected by ultracentrifugation at 100,000g for 2 h. For purification of circulating extracellular vesicles by differential centrifugation, venous citrated blood from melanoma patients or healthy donors was centrifuged at 1,550g for 30 min to obtain cell-free plasma (Beckman Coulter, Allegra X-14R). Then, 1 ml of the obtained plasma was centrifuged at 16,500g for 45 min (Eppendorf, 5418R). The pelleted microvesicles were suspended in PBS. The collected supernatants were then centrifuged at 100,000g for 2 h at 4 °C (Beckman Coulter, Optima TM MAX-XP) to pellet the exosomes. For purification of circulating exosomes using the exosome isolation kit, cell-free plasma was first centrifuged at 16,500g for 45 min (Eppendorf, 5418R) to pellet large membrane vesicles. Exosomes were then purified from the supernatants using the exosome isolation kit (Invitrogen, Cat# 4484450).
Characterization of purified exosomes. For verification of purified exosomes using electron microscopy, purified exosomes suspended in PBS were dropped on formvar carbon-coated nickel grids. After staining with 2% uranyl acetate, grids were air-dried and visualized using a JEM-1011 transmission electron microscope. For immunogold labelling, purified exosomes suspended in PBS were placed on formvar carbon-coated nickel grids, blocked, and incubated with mouse anti-human monoclonal antibody that recognizes the extracellular domain of PD-L1 (clone 5H1-A3) 1 , followed by incubation with the anti-mouse secondary antibody conjugated with protein A-gold particles (5 nm). Each staining step was followed by five PBS washes and ten ddH 2 O washes before contrast staining with 2% uranyl acetate.
The size and concentration of exosomes purified from cell culture supernatants or patients' plasma were determined using a NanoSight NS300 (Malvern Instruments), which is equipped with fast video capture and particle-tracking software.
For iodixanol density gradient centrifugation, exosomes harvested by differential centrifugation were loaded on top of a discontinuous iodixanol gradient (5%, 10%, 20% and 40%, made by diluting 60% OptiPrep aqueous iodixanol with 0.2 5M sucrose in 10 mM Tris) and centrifuged at 100,000g for 18 h at 4 °C (Beckman Coulter, Optima MAX-XP). Twelve fractions of equal volume were collected from the top of the gradients, with the exosomes distributed at the density range between 1.13 and 1.19 g/ml, as previously demonstrated 8, 9, 11, 12 . The exosomes were further pelleted by ultracentrifugation at 100,000g for 2 h at 4 °C. Immunoprecipitation. To analyse the role of ESCRT machinery in exosomal secretion of PD-L1 in melanoma cells, PD-L1/MEL624 cells were transfected with Flag-Hrs plasmid or vector and then lysed. The cleared lysate was incubated with Anti-FLAG Affinity Gel (Sigma-Aldrich) overnight at 4 °C. The immunoprecipitated proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. PD-L1 and Flag (Hrs) were determined by western blot using specific antibodies. ELISA. For detection of PD-L1 on extracellular vesicles, cell supernatants or patients' plasma, ELISA plates (96-well) (Biolegend) were coated with 0.25 μg per well (100 μl) of monoclonal antibody against PD-L1 (clone 5H1-A3) overnight at 4 °C. Free binding sites were blocked with 200 μl of blocking buffer (Pierce) for 1 h at room temperature. Then, 100 μl of plasma samples with or without extracellular vesicle removal, or extracellular vesicle samples purified from plasma or cell culture supernatants, were added to each well. The exosome or microvesicle samples purified from cell culture supernatants were prepared by serial dilution according to the total protein level to analyse the enrichment of PD-L1 on exosomes and microvesicles. The concentration of PD-L1 on the surface of exosomes isolated from indicated cells was calculated based on the linear range of the ELISA assay data. The exosome or microvesicle samples derived from the plasma samples of healthy donors or melanoma patients were prepared using the same volume of PBS as the plasma as they were originally derived from. The plasma samples with (extracellular vesicle-excluded) or without (total) extracellular vesicle removal were diluted with PBS in a 1:0.75 volume ratio. After overnight incubation at 4 °C, biotinylated monoclonal PD-L1 antibody (clone MIH1, eBioscience) was added to each well and incubated for 1 h at room temperature. A total of 100 μl per well of horseradish peroxidase-conjugated streptavidin (BD Biosciences) diluted in PBS containing 0.1% BSA was then added and incubated for 1 h at room temperature. Plates were developed with tetramethylbenzidine (Pierce) and stopped with 0.5N H 2 SO 4 . The plates were read at 450 nm with a BioTek plate reader. Recombinant human PD-L1 protein (R&D Systems, Cat# 156-B7) was used to make a standard curve. Recombinant P-selectin protein (R&D Systems, Cat# 137-PS) was used as negative control to verify the detection specificity. The result of standard curve demonstrated that the established ELISA exhibited a reliable linear detection range from 0.2 to 12 ng/ml.
For detection of IFN-γ, TNF and IL-2, the supernatant of human CD8 T cells was harvested and measured according to the kit manufacturer's instructions (Biolegend).
PD-1-PD-L1 binding assay.
To test the binding of exosomal PD-L1 to PD-1, 100 μl of exosome samples of different concentrations were captured onto PD-L1 antibody (clone 5H1-A3)-coated 96-well ELISA plates by overnight incubation at 4 °C. Then 100 μl of 4 μg/ml biotin-labelled human PD-1 protein (BPS Bioscience, Cat# 71109) was added and incubated for 2 h at room temperature. A total of 100 μl per well of horseradish peroxidase-conjugated streptavidin (BD Biosciences) diluted in PBS containing 0.1% BSA was then added and incubated for 1 h at room temperature. Plates were developed with tetramethylbenzidine (Pierce) and stopped using 0.5N H 2 SO 4 . The plates were read at 450 nm with a BioTek plate reader. Recombinant human PD-L1 protein directly coated onto the plates was used as the positive control.
Treatment of CD8 T cells with the exosomes.
To block PD-L1 on the exosome surface, purified exosomes (200 μg) were incubated with PD-L1 blocking antibodies (10 μg/ml) or IgG isotype antibodies (10 μg/ml) in 100 μl PBS, and then washed with 30 ml PBS and pelleted by ultracentrifugation to remove the non-bound free antibodies. Human CD8 T cells purified from peripheral blood using Letter reSeArCH immunodepletion on a Ficoll-Hypaque gradient (RosetteSep, StemSep Technologies) or mouse CD8 T cells purified from splenocytes using Dynabeads Untouched Mouse CD8 Cells Kit (Invitrogen) were stimulated with anti-CD3 (2 μg/ml) and anti-CD28 (2 μg/ml) antibodies for 24 h and then incubated with human melanoma cell-derived exosomes or mouse B16-F10 cell-derived exosomes with or without PD-L1 blocking for 48 h in the presence of anti-CD3/CD28 antibodies. For human CD8 T cells (2 × 10 5 cells/well in a 96-well plate), 25 μg/ml of human WM9 cell-derived exosomes (carrying surface PD-L1 at a level of 0.05 ng per μg of exosomes as determined by ELISA, Fig. 1i ) were used as the circulating exosomal PD-L1 level in melanoma patients is around 1.25 ng/ml (Fig. 2h ). For mice CD8 T cells (2 × 10 5 cells/well in a 96-well plate), 100 μg/ml of mouse B16-F10 cellderived exosomes (carrying surface PD-L1 at a level of 0.016 ng per μg of exosomes as determined by ELISA) were used as the circulating exosomal PD-L1 level in mice bearing B16-F10 tumours is around 1.63 ng/ml. The treated cells were then collected, stained, and analysed by flow cytometry. Information about the primary antibodies is included in Supplementary Table 2 . To assay for the proliferation of CD8 T cells, CFSE, a dye for the tracking of cell division (Molecular Probes) was used. A total of 1 × 10 6 CD8 T cells were stained with CFSE at 5 μM. The cells were then incubated at 37 °C for 20 min and the reaction was stopped by adding 5 volumes of cold medium with 10% FBS, and treated as above. Unstimulated CFSE-labelled cells served as a non-dividing control. The exosome-T cell binding assay. To verify the physical interactions between melanoma cell-derived exosomes and CD8 T cells, purified exosomes were stained with CFSE in 100 μl PBS, and then washed with 10 ml PBS and pelleted by ultracentrifugation. Unstimulated or stimulated human CD8 T cells (2 × 10 5 cells/well in 96-well plates) were treated with CFSE-labelled exosomes (25 μg/ml) for 2 h, and then fixed for flow cytometry or confocal microscopy after immunostaining for CD8 T cells.
Generation of dendritic cells from bone marrow. Dendritic cells (DCs)
were generated from bone marrow of C57BL/6 mice and cultured in RPMI 1640 with 10% (v/v) FBS, 20 mM l-glutamine, 50 μM β-mercapoethanol, 20 ng/ml IL-4 and 20 ng/ml GM-CSF. After 3 days, half of the culture medium was replaced by fresh medium containing 40 ng/ml IL-4 and 40 ng/ml GM-CSF. To prime antigenspecific OT-I CD8 T cells, DCs were subsequently loaded with 2 μg/ml SIINFEKL (OVA 257-264 ) peptide overnight. CD8 T cell-mediated tumour cell killing assay. To determine the effects of melanoma cell-derived exosomes on the ability of CD8 T cells to kill tumour cells, CD8 T cells were purified from the splenocytes of OT-I mice expressing a transgene encoding a T cell receptor that specifically recognized SIINFEKL peptide bound to MHC-I H-2k b32 . OT-I CD8 T cells (4 × 10 5 cells/well in a 48-well plate) were then activated by incubation with SIINFEK-loaded (2 μg/ml) bone marrow-derived DCs (2 × 10 5 cells/well). The activated OT-I CD8 T cells (4 × 10 5 cells/well in 48-well plate) were treated with PBS (as a control) or B16-F10-derived exosomes (100 μg/ml for 48 h) with or without IgG isotype or PD-L1 antibody blocking (10 μg/ml), and then co-cultured with CFSE-labelled melanoma PD-L1 (KD) B16/OVA cells (4 × 10 5 ) in 6-well plates for 48 h at an effector to target (E:T) ratio of 1:1. Cells were then harvested, intracellularly stained with BV650-conjugated antibody against cleaved-caspase-3 (BD Biosciences) and analysed by flow cytometry. Information about the primary antibodies is included in Supplementary Table 2 . Immunofluorescence staining. Immunofluorescence staining was performed on fixed cells or formalin-fixed, paraffin-embedded (FFPE) sections. For fixed cells, permeabilization with 0.1% Triton X-100 was performed before blocking with bovine serum albumin (BSA) buffer for 1 h. For FFPE sections, antigen retrieval by steaming in citrate buffer (pH = 6.0) was performed before blocking. The fixed cells or FFPE sections were incubated with primary antibodies overnight at 4 °C, followed by incubation with fluorophore-conjugated secondary antibodies for 1 h. Nuclei were stained with DAPI. Samples were observed using a Nikon confocal microscope at 100× magnification. Western blot analysis. Whole cell lysates or exosomal proteins were separated using 12% SDS-PAGE and transferred onto nitrocellulose membranes. The blots were blocked with 5% non-fat dry milk at room temperature for 1 h, and incubated overnight at 4 °C with the corresponding primary antibodies at dilutions recommended by the suppliers, followed by incubation with HRP-conjugated secondary antibodies (Cell Signaling Technology) at room temperature for 1 h. The blots on the membranes were developed with ECL detection reagents (Pierce). CD63, Hrs, Alix, and TSG101 were used as exosome markers. TYRP-1 and TYRP-2 were used as melanoma-specific markers. GAPDH was used as a loading control. Information about the primary antibodies was included in Supplementary Table 2 . Quantitative PCR (qPCR). Total RNA was isolated from CD8 T cells using TRIzol Reagent (Invitrogen), and reverse transcribed into first-strand complementary DNA (cDNA) with random primer with RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific). The samples were then analysed in an Applied Biosystems QuantStudio 3 Real-Time PCR system. GAPDH was used as an internal control. Information about the primers is included in Supplementary Table 3 .
In vivo mice study. All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania. For establishing human melanoma xenograft model in nude mice, WM9 cells (5 × 10 6 cells in 100 μl medium) were injected into flanks of 8-week-old female athymic nude mice. Tumours were measured using a digital caliper and the tumour volume was calculated by the formula: (width) 2 × length/2. Mice were euthanized 30 days after cell inoculation or if the longest dimension of the tumours reached 2.0 cm before 30 days. Immediately following euthanasia, blood samples were harvested by cardiac puncture, and exosomes were purified and detected by ELISA using the aforementioned method. Exosomes purified from sex-, age-and weight-matched healthy nude mice without xenograft were used as the control.
For establishing syngeneic mouse melanoma model in C57BL/6 mice, B16-F10 cells or B16-F10 PD-L1 (KD) cells (5 × 10 5 cells in 100 μl medium) were subcutaneously injected into immunocompetent C57BL/6 mice. Based on the difference in the level of circulating exosomal PD-L1 between mice bearing parental B16-F10 and PD-L1 (KD) B16-F10 tumours (1.63 ng/ml vs 0.70 ng/ml), a total of 100 μg of parental B16-F10 cell-derived exosomes (carrying surface PD-L1 at a level of 0.016 ng per μg of exosomes) with or without IgG isotype, CD63 or PD-L1 blocking (10 μg/ml) were injected into mice after inoculation of PD-L1 (KD) B16-F10 cells to examine the functional significance of PD-L1. The dose of 100 μg exosomes used for our in vivo study was equivalent to approximately 30% of the physiological level of circulating exosomes in mice, and was also comparable to those from a palpable tumour in mice according to our data. Tail vein injections of exosomes (100 μg in 100 μl PBS) were performed every 3 days. Mice were weighed every 3 days. Tumours were measured using a digital caliper and the tumour volume was calculated by the formula: (width) 2 × length/2. The mice were euthanized before the longest dimension of the tumours reached 2.0 cm. Mice were allocated randomly to each treatment group. Downstream analyses of mouse samples (immunofluorescence staining, flow cytometry and ELISA) were performed in a blinded fashion. For flow cytometry, the spleen and tumour samples were harvested, and single cell suspensions were prepared and red blood cells were lysed using ACK Lysis Buffer. Information about the primary antibodies is included in Supplementary Table 2 . Reverse phase protein array (RPPA). RPPA was performed at the MD Anderson Cancer Center core facility using 50 μg protein per sample. All of the antibodies were validated by western blot 13 . Methods for data analysis are described below. Statistical analyses. RPPA data analysis was performed according to the protocol from the MD Anderson Cancer Center. Specifically, relative protein levels for each sample were determined by interpolation of each dilution curve from the 'standard curve' (supercurve) of the slide (antibody). Supercurve is constructed by a script in R written by the RPPA core facility. The package binaries of SuperCurve and SuperCurveGUI are available in R-Forge (https://r-forge.r-project.org/R/?group_ id=1899). These values are defined as supercurve log 2 value. All the data points were normalized for protein loading and transformed to linear value, designated as 'normalized linear' . Normalized linear value was transformed to the log 2 value, and then median-centred for further analysis. Median-centred values were obtained by subtracting the median of all samples in a given protein. All of the abovementioned procedures were performed by the RPPA core facility. The normalized data provided by the RPPA core facility were analysed by Cluster 3.0 (http:// bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/) and visualized using the Java TreeView 1.0.5 (http://jtreeview.sourceforge.net/). All other statistical analyses were performed using GraphPad Prism v.6.0. Normality of distribution was determined by D' Agostino-Pearson omnibus normality test and variance between groups was assessed by the F-test. For normally distributed data, significance of mean differences was determined using two-tailed paired or unpaired Student's t-tests; for groups that differed in variance, unpaired t-test with Welch's correction was performed. For data that were not normally distributed, non-parametric Mann-Whitney U-tests or Wilcoxon matched-pairs tests were used for unpaired and paired analysis, respectively. Correlations were determined by Pearson's r coefficient. Two-way ANOVA was used to compare mouse tumour volume data among different groups. log-rank and Wilcoxon tests were used to analyse the mouse survival data. Error bars shown in graphical data represent mean ± s.d. A two-tailed value of P < 0.05 was considered statistically significant. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. All data and materials are available from the authors upon reasonable request. -test (a, d, e, g, h, l) . For gel source data (b, c, f-i, l) , see Supplementary Fig. 1 . 
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Extended Data Fig. 3 | The number or bulk protein level of circulating exosomes shows no or modest difference between healthy donors and patients with metastatic melanoma. a, ELISA showing the level of PD-L1 on circulating exosomes purified from healthy donors (HD, n = 11) and melanoma patients (MP, n = 44). The exosomes were purified using differential centrifugation. b, Pearson correlation between the ELISA-detected levels of PD-L1 on circulating exosomes purified by differential centrifugation or using the commercial exosome isolation kit (n = 44). c, Comparison of the number of circulating exosomes between healthy donors (n = 10) and melanoma patients (n = 38). d, Comparison of the protein content of circulating exosomes between healthy donors (n = 10) and melanoma patients (n = 38). e, ELISA of the circulating level of microvesicle PD-L1 in healthy donors (HD, n = 11) and melanoma patients (MP, n = 44). f, Detailed data associated with the ROC curve analysis depicted in Fig. 2g . Data represent mean ± s.d. Statistical analyses are performed by two-sided unpaired t-test (a, c-e). 
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Mycoplasma contamination
All the cell lines presented in this study were tested for mycoplasma contamination and they were free of mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Research animals
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Animals/animal-derived materials Eight-week-old female athymic nude mice were used to establish melanoma xenograft. Six-to-eight-week-old, female and male, immunocompetent C57BL/6 mice were used to establish mouse melanoma model.
Human research participants
Policy information about studies involving human research participants The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
For characterization of exosomal PD-L1, purified exosomes were incubated with CD63-coated magnetic beads in 100 μl of isolation buffer (PBS with 0.1% BSA) overnight at 4 °C with mixing. Then, the exosome-bound beads were washed twice with isolation buffer and incubated with fluorophore-labeled anti-PD-L1 antibodies for 60 min at 4 °C . For analyzing the level of cleaved-Caspase-3, cells were collected and washed, and then fixed and permeabilized with the FOXP3 Fixation/Permeabilization Concentrate and Diluent kit, followed by staining with fluorophore-labeled anti-active Caspase-3 antibodies for 60 min on ice. For analyzing purified human or mouse CD8 T cells, cells with different treatments were first incubated with anti-CD16/CD32 antibodies for 10 min, and then stained with a fixable Aqua viability dye and a cocktail of antibodies for the surface markers for 30 min on ice. Cells were then fixed and permeabilized with the FOXP3 Fixation/Permeabilization Concentrate and Diluent kit, and subsequently stained for intracellular markers for 60 min on ice. For analyzing tumor-infiltrating, splenic or lymph node T cells from mice, the tumor, spleen and lymph node samples were harvested for preparation of single cell suspensions. Red blood cells were lysed using ACK lysis buffer. Single cell suspensions were then incubated with anti-CD16/CD32 antibodies for 10 min, and then stained with a cocktail of antibodies for the surface markers for 30 min on ice. After that, cells were fixed and permeabilized, and subsequently stained for intracellular markers for 60 minutes on ice.
Instrument LSR II cytometer (BD Biosciences)
Software
FACSDiva software (BD Biosciences) was used to collect events on the LSR II, and FlowJo software (TreeStar) was used to analyze the data.
Cell population abundance N/A
Gating strategy
Single cell gates based on FSC-H and FSC-A, and SSC-H and SSC-A were used to exclude non-singlets. A morphology gate based on FSC-A and SSC-A was used to exclude debrees. A live/dead cell gate based on fixable viability dye was used to exclude dead cells. For analyzing the positivity of cleaved-Caspase-3 in cells, cells stained with isotype control antibodies were used to define the background non-specific staining, and then a cleaved-Caspase-3+ gate was used for cells stained with cleaved-Caspase-3 6 nature research | reporting summary
March 2018 specific antibodies based on the background. For identifying CD8 T cells, a CD3+CD8+CD4-gating strategy was used. For analyzing the PD-1 expression and activation status of CD8 T cells, CD3+CD8+CD4-cells were gated for PD-1, Ki-67 and GzmB. For analyzing CD8 T cell proliferation using the CFSE dilution assay, divided cells showing diluted CFSE were gated by taking unstimulated CFSE-labeled cells and non-labeled cells as the controls, which showed the CFSE intensity of non-divided cells and auto-fluorescence of the cells, respectively.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
